In pregnant patient

Infliximab is FDA category B and also appears to carry minimal risk in pregnant patients. Little is known about excretion of infliximab in breast milk, so benefit versus risk should be considered if it is used during nursing. 

The pediatric dose of paromomycin is the same as that used in adults, whereas the pediatric dose of iodoquinol is 30 to 40 mg/kg (maximum 2 g) per day in three doses for 20 days, and the pediatric dose of diloxanide furoate is 20 mg/kg per day in three doses for 10 days. Paromomycin is the preferred agent in pregnant patients.3... 

Topical podophyllin is applied once weekly and the area should be allowed to dry. Immediately following treatment, the dried drug should be removed using alcohol or soap and water. Contraindicated in pregnant patients. 

Not reliably bactericidal should not be used for endocarditis. eNot for use in pregnant patients or children younger than 8 years old. 

Because of the possibility of hemolytic anemia caused by immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients P.1001... 

Because epidural opioids are usually ineffective in controlling pain during the final stages of labour they are commonly combined with a low concentration of a local anaesthetic, e.g. 0.125% bupivacaine. There has been speculation that epidural opioids may reactivate herpes simplex in pregnant patients. The aetiology is unclear. Herpes simplex after delivery is potentially dangerous because of the risk of herpes encephalitis in the infant. Spinal opioids should therefore be avoided in the parturient with a history of recurrent herpes simplex. 

Oral pyogenic granulomata have been reported both in pregnant patients and in patients using oral contraceptives (203). 

Stika CS, Andrews W, Erederiksen MC, Mercer B, Sabai B, Antal E. Steady state pharmacokinetic study of Flagyl ER in pregnant patients during the second to third trimester of pregnancy [abstract]. Clin Pharmacol Ther 2004 75 P24. 

Ostensen M, Ostensen H. Safety of nonsteroidal antiinflammatory drugs in pregnant patients with rheumatic disease. J Rheumatol 1996 23(6) 1045-9. 

Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases A study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003 48 3207-3211. 

Only for soft tissue infections or upper respiratory infections (pharyngitis, otitis media). Wo not use in pregnant patients. 

Although not recommended as first-line therapy in pregnant patients with chlamydial infections because of limited data on its safety, azithromycin is the only agent with documented efficacy in a single dose. 

Sotalol should be used cautiously in pregnant patients and patients with renal failure or diabetes mellitus. Sotalol should be used with extreme caution in patients with sick-sinus syndrome associated with symptomatic arrhythmias, because the drug can cause sinus bradycardia, sinus pauses, or sinus arrest. 

Triazolam is contraindicated in patients in coma, because the drug s hypnotic or hypotensive effect may be prolonged or intensified in pregnant patients, because it may be feto-toxic and in patients with acute alcohol intoxication who have depressed vital signs, because the drug will worsen CNS depression. 

Transient and mild GI symptoms occasionally are observed, as are headache, dizziness, rash, and fever. Pyrantel pamoate use in pregnant patients and children <2 years of age is not recommended. Because pyrantel pamoate and piperazine are mutually antagonistic in their neuromuscular effects on parasites, they should not be used together. 

---